Filters
Singapore’s Health Sciences Authority (HSA) has granted a conditional approval to remdesivir for the treatment of severe COVID-19, sparking hope for that elusive cure.
By reducing hepatic enzyme levels and improving markers of hepatic steatosis or fibrosis, bariatric surgery may help reduce the risk of non-alcoholic fatty liver disease (NAFLD), according to a study from Portugal presented at ENDO 2020.
The combination of atezolizumab and bevacizumab (atezo-bev) delivered better overall survival (OS) and progression-free survival (PFS) outcomes than sorafenib in patients with untreated, locally advanced metastatic or unresectable hepatocellular carcinoma (HCC), the phase III IMbrave150 trial has shown.
Women are less likely to develop nonalcoholic fatty liver disease (NAFLD), although they are at higher risk of progression to advanced fibrosis once NAFLD is established as compared with men, a study reports.
Obesity appears to be a strong risk factor for liver-related mortality, while exercise exerts a protective effect, a recent study has found.
Cirrhotic survivors of acute kidney injury (AKI) are likely to develop chronic kidney disease, which, in turn, worsens outcomes, a recent study has found.
Liver cirrhosis patients with afebrile bacteraemia remain at risk of worse clinical outcomes and survival, a recent study has shown.
